T-cell receptor – Major Histocompatibility Complex class II interface (TCR-MHC II interface)

The T-cell receptor – Major Histocompatibility Complex class II (TCR-MHC II) interface is a fundamental molecular junction in the adaptive immune system, responsible for the recognition of exogenous antigens by CD4+ T helper cells (Hennecke & Wiley, 2001, Cell). This interface is formed when a TCR on a T lymphocyte binds to a peptide fragment presented within the binding groove of an MHC class II molecule on an antigen-presenting cell, such as a dendritic cell or B cell (Janeway's Immunobiology, 9th Ed). This interaction serves as the primary signal for T-cell activation, orchestrating downstream immune responses including cytokine production and B-cell help. In many autoimmune diseases, specific MHC II alleles (e.g., HLA-DRB1 in rheumatoid arthritis) inappropriately present self-peptides to autoreactive TCRs, leading to chronic inflammation and tissue destruction (Kwok et al., 2001, Trends in Immunology). Therapeutic strategies targeting this interface aim to disrupt these pathogenic interactions or induce antigen-specific tolerance. For example, glatiramer acetate acts as a decoy by competing with myelin-derived peptides for binding to MHC II molecules, thereby modulating the immune response in multiple sclerosis (Arnon & Aharoni, 2004, PNAS). Other approaches include the development of monoclonal antibodies and altered peptide ligands designed to sterically hinder or modify the TCR-MHC II engagement.

Other names

TCR-pMHC II complexT-cell receptor-MHC II interactionCD4 TCR-MHC II interfaceAntigen-MHC-TCR complex

Competitive inhibition of peptide binding to the MHC class II groove and steric blockade of the T-cell receptor binding site to prevent the formation of a functional immunological synapse and subsequent T-cell activation.